Ernexa Showcases ERNA-101 in KOL Segment and Highlights 100% Survival Preclinical Data
ERNA•Ernexa released a Virtual Investor KOL Connect segment where CSO Dr. Robert Pierce detailed the ovarian cancer landscape and introduced lead therapy candidate ERNA-101. The company scheduled a May 13 Closing Bell event to discuss preclinical ERNA-101 data showing complete tumor elimination and 100% survival in ovarian cancer models.
1. Virtual Investor KOL Connect Segment
Ernexa released a Virtual Investor KOL Connect featuring CSO Dr. Robert Pierce, who outlined the complexities of ovarian cancer treatment, discussed current therapy limitations and presented the biological rationale and mechanism of action behind its lead cell therapy candidate ERNA-101.
2. Upcoming Closing Bell Event
Ernexa’s CEO Sanjeev Luther and Dr. Pierce will participate in a Virtual Investor Closing Bell on May 13 at 4:00 PM ET, offering a corporate overview and an in-depth discussion of ERNA-101’s recently announced preclinical ovarian cancer data.
3. Preclinical Ovarian Cancer Data
Ernexa’s preclinical studies demonstrated that ERNA-101, when combined with PD-1 blockade, achieved complete tumor elimination and 100% survival in ovarian cancer models, suggesting its potential to reshape tumor microenvironments and enhance patient outcomes.
